RASDEGAFUSP ALFA

also known as CDX-1401 · DEC-205/NY-ESO-1 Fusion Protein CDX-1401

Developed for: ovarian carcinoma · chronic myelomonocytic leukemia · cutaneous melanoma · fallopian tube carcinoma · non-small cell lung carcinoma · primary peritoneal carcinoma · urothelial carcinoma · acute myeloid leukemia
+31 more
· acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent · anaplastic astrocytoma · anaplastic oligoastrocytoma · anaplastic oligodendroglioma · brain neoplasm · cancer · carcinoma of esophagus · colorectal carcinoma · estrogen-receptor negative breast cancer · estrogen-receptor positive breast cancer · female breast carcinoma · gastric carcinoma · glioblastoma · hepatocellular carcinoma · hormone-resistant prostate carcinoma · lung carcinoma · melanoma · mesothelioma · metastatic melanoma · metastatic prostate carcinoma · mucosal melanoma · myelodysplastic syndrome · ocular melanoma · refractory anemia with excess blasts in transformation · renal cell adenocarcinoma · sarcoma · small cell lung carcinoma · triple-negative breast carcinoma · urinary bladder carcinoma · uterine carcinoma · uterine corpus cancer
Investigated by: Celldex Therapeutics · National Cancer Institute (NCI) · Roswell Park Cancer Institute · Case Comprehensive Cancer Center · Incyte Corporation · Yale University

Trials 10 · a red edge is where a trial was stopped

today NCT03358719 · Ph 1 NCT03206047 · Ph 1/2 NCT02661100 · Ph 1/2 NCT02495636 · Ph 2 NCT02413827 · Ph 1/2 NCT02166905 · Ph 1/2 NCT02129075 · Ph 2 NCT01834248 · Ph 1 NCT01522820 · Ph 1 NCT00948961 · Ph 1/2

201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 13 trials
Phase 1	NCT03358719	Mar 2018 → Feb 2020	acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1	NCT01834248	Jul 2013 → Jun 2015	acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent, chronic myelomonocytic leukemia, refractory anemia with excess blasts in transformation	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1	NCT01522820	Mar 2012 → Jul 2016	anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, brain neoplasm +19	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1/25 trials
Phase 1/2	NCT03206047	Nov 2017 → Nov 2020	fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT02661100	Jan 2017 → Jul 2018	melanoma, mesothelioma, non-small cell lung carcinoma, small cell lung carcinoma +2	Case Comprehensive Cancer Center	Withdrawn	No outcome recorded
Phase 1/2	NCT02413827	Apr 2015 → Nov 2016	metastatic melanoma	Celldex Therapeutics	Terminated	No outcome recorded
Phase 1/2	NCT02166905	Oct 2014 → Aug 2020	fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma	Roswell Park Cancer Institute	Completed	No outcome recorded
Phase 1/2	NCT00948961	Sep 2009 → Jun 2012	cancer	Celldex Therapeutics	Completed	No outcome recorded
Phase 22 trials
Phase 2	NCT02495636	Jul 2015 → Jul 2017	non-small cell lung carcinoma	Yale University	Withdrawn	No outcome recorded
Phase 2	NCT02129075	Apr 2014 → Mar 2016	cutaneous melanoma, mucosal melanoma, ocular melanoma	National Cancer Institute (NCI)	Completed	No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

Field	Value	Cited text
Known as	RASDEGAFUSP ALFA	ChEMBL registry synonym — accepted as the source's own label CHEMBL4297923 ↗
Known as	CDX-1401	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00948961 ↗ 8 NCT01834248 ↗ NCT02495636 ↗ NCT02413827 ↗ NCT02129075 ↗ NCT02661100 ↗ NCT02166905 ↗ NCT03358719 ↗ NCT03206047 ↗
Known as	DEC-205/NY-ESO-1 Fusion Protein CDX-1401	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01522820 ↗
Modality	Vaccine	“CDX-1401 is a cancer vaccine” NCT00948961 ↗
Route	Other	“CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses.” NCT00948961 ↗
Target	CTAG1B	“Cancer/testis antigen 1 vaccine antigen” CHEMBL4297923 ↗
Target	LY75	“Lymphocyte antigen 75 binding agent” CHEMBL4297923 ↗